Mumbai: Venus Remedies Ltd has brought in a nanotechnology based ‘ready-to-use’ single vial Docetaxel in the domestic market.
The medicine is a single vial formulation available in three strengths and will be another tool in the Rs 1,500-crore cancer drug industry.
“`The one-vial formulation has the advantage of a single dilution step prior to administration. This offers a cost-effective solution to patients,’’ said Mr Mufti Suhail Sayeed, Vice-President, Venus Remedies Ltd.
He added that the novel technology would offer significant therapeutic advantage over all available similar and competing products.
Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.
According to the company, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.
The company is marketing the drug in Africa, CIS and Latin America. The grant of European Market Authorisation for Portugal has further opened up new grounds for Venus Remedies to cater to the EU market.
No comments:
Post a Comment